Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow NVCT by emailGet an email when NVCT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NVCT, unsubscribe in one click. Privacy
📣 What NVCT Says Is Next
in 2026 · “NXP100 Competitive Landscape and Market Analysis · The PNH market size is expected to be >$5.0BN in 2026 with the injectable C5 inhibitor drugs Soliris ® and Ultomiris ® , marketed by Alexion/AstraZeneca Rare Disease, projected to be approximately $4.5BN of the total market.”
Company press release, Jun 23, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full NVCT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVCT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.